Loading
A phase 3 trial of Golidocitinib run by Dizal Pharmaceuticals, now recruiting.
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) is a phase 3 interventional study registered as NCT07234162 by Dizal Pharmaceuticals, with 218 participants planned, started 2024-05-13. Conditions listed: Peripheral T-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Golidocitinib, Dizal Pharmaceutical, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Small-molecule kinase inhibitors.
Shares Golidocitinib, Dizal Pharmaceutical.
Shares Golidocitinib, Dizal Pharmaceutical.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors.
Shares Golidocitinib, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/